Pacylex to Meet with Investors at Bio CEO Conference (BCIC) in New York

CEO Michael Weickert will attend the upcoming BIO CEO & Investor Conference in NYC and will be meeting with investors regarding the company's Series B funding round. The company's lead candidate, zelenirstat, is a first-in-class, orally bioavailable small molecule myristoylation inhibitor, a new mechanism of action for cancer treatment. Zelenirstat is currently being studied in patients who have failed available treatments (refractory or relapsed; r/r). It is in Phase 2 for patients with r/r B-cell non-Hodgkin lymphoma (NHL) and is about to begin Phase 2a in various r/r solid tumors, especially colorectal cancer, and Phase 1/2 in r/r acute myeloid leukemia (AML). Pacylex recently presented Phase 1 results in gastrointestinal cancers at the ASCO-GI conference in San Francisco in January 2024, including a colorectal patient who had been on therapy for more than 340 days and counting with a reduction in tumor volume and blood cancer marker.